Prialt Patent Expiration

Prialt is a drug owned by Tersera Therapeutics Llc. It is protected by 5 US drug patents filed from 2013 to 2017 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 01, 2024. Details of Prialt's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765680 Method for administering omega-conopeptide
Oct, 2024

(a month ago)

Expired
US8653033 Method for administering omega-conopeptide
Oct, 2024

(a month ago)

Expired
US9707270 Method for administering ω-conopeptide
Oct, 2024

(a month ago)

Expired
US5364842 Method of producing analgesia
Dec, 2016

(7 years ago)

Expired
US5795864 Stable omega conopetide formulations
Jun, 2015

(9 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prialt's patents.

Given below is the list of recent legal activities going on the following patents of Prialt.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 15 Dec, 2021 US8765680
Payment of Maintenance Fee, 8th Year, Large Entity 04 Aug, 2021 US8653033
Email Notification 26 Apr, 2021 US8765680
Change in Power of Attorney (May Include Associate POA) 26 Apr, 2021 US8653033
Email Notification 26 Apr, 2021 US8653033
Change in Power of Attorney (May Include Associate POA) 26 Apr, 2021 US8765680
Correspondence Address Change 23 Apr, 2021 US8653033
Change in Power of Attorney (May Include Associate POA) 23 Apr, 2021 US9707270
Correspondence Address Change 23 Apr, 2021 US8765680
Email Notification 23 Apr, 2021 US9707270

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Prialt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prialt's family patents as well as insights into ongoing legal events on those patents.

Prialt's Family Patents

Prialt has patent protection in a total of 4 countries. It has a significant patent presence in the US with 77.3% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Prialt.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Prialt's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 01, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Prialt Generics:

There are no approved generic versions for Prialt as of now.

Alternative Brands for Prialt

Prialt which is used for managing severe chronic pain through intrathecal infusion in patients also receiving morphine., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Btcp Pharma
Subsys Used for managing pain.
Fresenius Kabi Usa
Morphine Sulfate Used for managing chronic pain and treating pain in patients requiring opioid analgesia.
Genus
Tivorbex Used for relieving pain.
Recro Gainesville
Zohydro Er Used for managing pain in patients with hepatic impairment.
Upjohn
Lyrica used for managing fibromyalgia, treating various types of pain, and seizure disorders.
Zyla
Zorvolex Used for managing pain.





About Prialt

Prialt is a drug owned by Tersera Therapeutics Llc. It is used for managing severe chronic pain through intrathecal infusion in patients also receiving morphine. Prialt uses Ziconotide Acetate as an active ingredient. Prialt was launched by Tersera in 2004.

Approval Date:

Prialt was approved by FDA for market use on 28 December, 2004.

Active Ingredient:

Prialt uses Ziconotide Acetate as the active ingredient. Check out other Drugs and Companies using Ziconotide Acetate ingredient

Treatment:

Prialt is used for managing severe chronic pain through intrathecal infusion in patients also receiving morphine.

Dosage:

Prialt is available in injectable form for intrathecal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
500MCG/5ML (100MCG/ML) INJECTABLE Prescription INTRATHECAL
500MCG/20ML (25MCG/ML) INJECTABLE Prescription INTRATHECAL
100MCG/1ML (100MCG/ML) INJECTABLE Prescription INTRATHECAL
200MCG/2ML (100MCG/ML) INJECTABLE Discontinued INTRATHECAL